National Breast Cancer Coalition

National Breast Cancer Coalition
Name	National Breast Cancer Coalition
Formation	1991
Type	Nonprofit advocacy organization
Headquarters	Washington, D.C.
Leader title	Executive Director

National Breast Cancer Coalition is an American advocacy organization formed in 1991 to end breast cancer through advocacy, research funding, and policy change. The organization brings together activists, survivors, scientists, legislators, and foundations to pursue targeted goals in prevention, detection, treatment, and survivorship. It operates at the intersection of grassroots activism and federal policymaking, engaging with Capitol Hill, research institutions, and philanthropic networks.

History

The coalition was founded following conferences and organizing efforts that included participants from Susan G. Komen for the Cure, Breast Cancer Research Foundation, American Cancer Society, National Institutes of Health, and survivor-led groups such as Breast Cancer Action. Early leadership included activists who had worked with Gray Panthers, NOW (National Organization for Women), and ACT UP veterans. The organization emerged amid legislative efforts like the passage of the National Cancer Act and during the expansion of programs at the Centers for Disease Control and Prevention. Its formative campaigns intersected with policy debates around the Food and Drug Administration, National Institute of Environmental Health Sciences, and appropriations processes in the United States Congress. Over time the coalition collaborated with entities including the Wellcome Trust, Robert Wood Johnson Foundation, Ford Foundation, and academic centers such as Johns Hopkins University, Harvard Medical School, and Dana-Farber Cancer Institute.

Mission and Objectives

The coalition's mission emphasizes accelerating prevention and ending breast cancer by focusing on research, public policy, and accountability. Objectives reference measurable goals similar to those promoted by World Health Organization initiatives and align with strategies pursued by institutions like American Association for Cancer Research, National Academy of Sciences, and Institute of Medicine. Strategic priorities have included influencing funding at the National Cancer Institute, promoting clinical trial reforms at the National Institutes of Health Clinical Center, and shaping regulatory policy at the Food and Drug Administration.

Programs and Initiatives

Programs have included targeted advocacy training modeled after workshops at Harvard Kennedy School and partnership programs comparable to those run by Susan G. Komen for the Cure and Cancer Research UK. Initiatives have addressed clinical trial design in collaboration with investigators at Memorial Sloan Kettering Cancer Center, translational research projects with Fred Hutchinson Cancer Research Center, and community outreach aligned with programs at Centers for Disease Control and Prevention and Agency for Healthcare Research and Quality. The coalition launched campaigns to reform breast cancer screening guidelines discussed in forums with the U.S. Preventive Services Task Force and supported data-sharing initiatives reminiscent of efforts at The Cancer Genome Atlas and National Center for Biotechnology Information.

Advocacy and Policy Impact

The coalition has engaged in legislative advocacy before committees such as the United States House Committee on Appropriations and United States Senate Committee on Health, Education, Labor, and Pensions. It has advocated for appropriations increases at the National Cancer Institute and policy changes involving the Food and Drug Administration and the Centers for Medicare & Medicaid Services. The organization has testified alongside representatives from American Cancer Society Cancer Action Network, Leukemia & Lymphoma Society, and Alzheimer's Association on issues including clinical trial access, biomarker development, and federal research priorities. Coalition efforts have intersected with major laws and oversight hearings related to biomedical research funding in the United States Congress and with federal agencies including the Office of Management and Budget.

Research Funding and Partnerships

The coalition leverages partnerships with research institutions such as Cold Spring Harbor Laboratory, Salk Institute, Broad Institute, and university centers at University of California, San Francisco and Stanford University School of Medicine. Funding strategies have involved collaborations with philanthropic institutions like the Gordon and Betty Moore Foundation and programmatic alliances with consortia such as All of Us Research Program and registries reminiscent of Surveillance, Epidemiology, and End Results Program. The coalition has influenced grant priorities at the National Institutes of Health and worked with peer organizations including American Association for Cancer Research, Translational Research Institute, and international partners like Cancer Research UK.

Organizational Structure and Leadership

Governance typically includes a board of directors with members drawn from advocacy groups, scientific institutions, survivor networks, and philanthropic boards such as those that mirror membership at Robert Wood Johnson Foundation advisory panels. Staff roles include executive leadership, policy directors who engage with the United States Congress, and scientific advisors recruited from institutions including Johns Hopkins University School of Medicine, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute. Volunteer leadership has included survivors and activists with backgrounds in organizations such as Breast Cancer Action and NOW (National Organization for Women).

Criticism and Controversies

The coalition has faced scrutiny similar to debates surrounding Susan G. Komen for the Cure and Breast Cancer Research Foundation over priorities between research funding, advocacy tactics, and partnerships with pharmaceutical companies and large donors like the Gates Foundation. Critics from grassroots groups such as Breast Cancer Action and academic commentators at institutions like Columbia University have raised questions about research prioritization, allocation of advocacy resources, and engagement with industry stakeholders including major biotechnology firms and pharmaceutical companies represented in coalitions like PhRMA. Debates have also mirrored controversies involving clinical guideline disputes with the U.S. Preventive Services Task Force and funding allocation discussions within the National Cancer Institute.

Category:Cancer charities based in the United States